利格列汀对2型糖尿病患者血糖变化的影响

摘要

Objective To investigate the influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus (T2DM)and to evaluate its safety.Methods A total of 98 patients diagnosed with T2DM admitted in our hospital were randomly divided into treatment group and control group,49 cases for each.Control group was treated with insulin glargine concomitant with dimethyldiguanide,on which basis treatment group was added with 5 mg /d linagliptin.Fast-ing plasma glucose (FPG),plasma glucose 2 h after meals (2hPG),glycosylated hemoglobin (HbAlc),body mass index (BMI)and adverse response rate before and 12 weeks after treatment were compared between two groups.Results After 12 weeks treatment,FPG,2hPG and HbAlc reduced evidently than treatment before,and were more lower in treatment group than in control group (P <0.05),while BMI had no significant difference before and after treatment in both groups (P > 0.05 ).The main adverse responses included nasopharyngitis,hypoglycemia, headache,gastrointestinal reactions and upper respiratory infection,in which only upper respiratory infection rate was significantly different between two groups (P <0.05).Conclusion linagliptin plus insulin glargine concomitant with dimethyldiguanide can effectively control blood glucose changes in patients with T2DM,which deserves to be widely used in clinic.%目的：探讨利格列汀对2型糖尿病患者血糖变化的影响，并评估其安全性。方法选择本院收治的98例确诊为2型糖尿病患者，随机分为治疗组和对照组，每组49例。对照组给予甘精胰岛素联合二甲双胍治疗，治疗组在对照组基础上增加5 mg /d 利格列汀治疗。比较2组治疗前和治疗12周后的空腹血糖（FPG）、餐后2 h 血糖（2hPG）、糖化血红蛋白（HbAlc）、体质量指数（BMI）变化和不良反应发生率。结果治疗12周后，2组患者的 FPG、2 hPG 和 HbAlc 均有明显下降，但治疗组下降幅度显著高于对照组（P ＜0．05），BMI 在治疗前后无明显变化（P ＞0．05）。主要不良反应包括鼻咽炎、低血糖、头痛、胃肠道反应和上呼吸道感染等，治疗组上呼吸道感染的发生率明显低于对照组（P ＜0．05）。结论利格列汀联合甘精胰岛素及二甲双胍治疗2型糖尿病能有效控制患者血糖变化，值得在临床广泛使用。